Spirocyclic EBI2 Modulators for Autoimmune and Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases, cancer, and cardiovascular conditions, particularly those involving Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2), lack effective modulators to manage dysregulation and associated pathologies.
Innovation Solution
Development of spirocyclic compounds that modulate EBI2 activity, including pharmaceutical compositions and methods for administering these compounds to treat autoimmune diseases, cancer, and cardiovascular conditions by targeting EBI2-mediated signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune diseases, cancer, and cardiovascular conditions are used, then existing therapeutic options are available, but effective modulators to manage dysregulation and associated pathologies are lacking
Solution Approach 1:
The patent segments the therapeutic approach by developing distinct spirocyclic compound structures (Formula I) with specific molecular configurations that target EBI2 receptor. This segmentation creates specialized modulators with defined structural features (X, Y, R1, R2 groups) that can be optimized for specific therapeutic applications, resolving the lack of effective modulators while maintaining reliable therapeutic effects.
Solution Approach 2:
The patent applies parameter changes by systematically varying molecular parameters in the spirocyclic compound structure (different X linkers, Y substituents, R1 aryl/heteroaryl groups, R2 cyclic/aryl groups) to optimize EBI2 modulation. This allows creation of multiple modulator variants with different potency and selectivity profiles, addressing the versatility gap in current treatments while ensuring therapeutic reliability.
2Reliability
If spirocyclic compounds are developed to modulate EBI2 activity, then therapeutic benefits for autoimmune diseases, cancer, and cardiovascular conditions are provided, but the complexity of developing new pharmaceutical compositions increases
Solution Approach 1:
The spirocyclic compounds of Formula (I) are designed with universal applicability across multiple disease indications (autoimmune diseases, cancer, cardiovascular conditions) by targeting the common EBI2 receptor pathway. This multi-functionality approach allows a single compound class to provide therapeutic benefits across diverse conditions, reducing the need for separate complex formulations for each indication while maintaining reliable therapeutic effects.
Solution Approach 2:
The patent employs composite molecular structures combining spirocyclic core with various substituent groups (X, Y, R1, R2) to create pharmaceutical compositions with optimized properties. This composite approach allows systematic modification of molecular characteristics to enhance therapeutic benefits while managing composition complexity through structured design rather than random complexity.
Data Source
AI summary
Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.